We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Atropine vs Patching—Reply

Michael X. Repka, MD, MBA1; Raymond T. Kraker, MSPH2; Jonathan M. Holmes, BM, BCh3 ; for the Pediatric Eye Disease Investigator Group
[+] Author Affiliations
1Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, Maryland
2Jaeb Center for Health Research, Tampa, Florida
3Mayo Clinic, Rochester, Minnesota
JAMA Ophthalmol. 2015;133(5):619-620. doi:10.1001/jamaophthalmol.2014.6131.
Text Size: A A A
Published online


In Reply Dr Lempert raises several issues, which we believe are mistaken or do not affect the interpretation of our results. As described,1 only participants at sites with more than 5 enrolled children were eligible for long-term follow-up for logistical reasons, which reduced the proportion of the original cohort that was enrolled in the follow-up study. The 15-year examination was completed by 152 of 188 eligible participants (80.9%). We compared patients who participated in follow-up with those who did not and noted in the article that those who participated had slightly better VA at 2 years than those who did not (20/25 vs 20/32, respectively), which could have resulted in a slight overestimate of VA at age 15 years. In addition, 147 participants in Table 1 noted by Dr Lempert were only those who completed the visit at age 15 years and had VA tested with the electronic Early Treatment Diabetic Retinopathy Study testing protocol (E-ETDRS).2 Five participants had VA tested with a method other than E-ETDRS and were not included in the primary results.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





May 1, 2015
Philip Lempert, MD
1Arleo Eye Associates, Ithaca, New York
JAMA Ophthalmol. 2015;133(5):619. doi:10.1001/jamaophthalmol.2014.6111.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...